{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:50:46Z","timestamp":1774122646283,"version":"3.50.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The pentaazamacrocyclic superoxide dismutase mimetic, Avasopasem Manganese (AVA), has been shown in clinical trials to reduce the severity and duration of acute oral mucositis (OM) and acute esophagitis in patients treated for head and neck and lung cancers, respectively, by radiotherapy using conventional fractionation protocols. Here, the radioprotective effects of AVA were tested in normal tissues after high dose per fraction radiation exposures to determine whether: radioprotective effects of AVA were still present after doses like those used with stereotactic ablative radiotherapy (SAbR); AVA protected against late normal tissue responses; and, whether AVA could act as a radiomitigator of adverse normal tissue events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>With AVA, residual DNA lesions and micronuclei were reduced in HBEC3 KT but increased in H1299 cells 24h post-irradiation. Furthermore, radiation-induced mutations and chromosome aberrations were reduced in WTK-1 lymphoblast cells. The radioprotective effects of AVA at high dose per fraction were then tested against both acute and late normal tissue effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>When provided prior to radiation, AVA reduced the extent of epithelial cell layer degradation of mouse tongue irradiated with a single dose of 17 Gy and reduced radiation recall when a second dose of radiation of 12 or 17 Gy was given two weeks following the initial 17 Gy dose. In addition, when provided after radiation, there was a modest but significant reduction in adverse epithelial layer response. Radiation-induced lung fibrosis, determined at 24 weeks post-irradiation, was also reduced when AVA was delivered 1 hour prior to irradiation after a single dose of 54 Gy. When AVA was provided 24h after 54 Gy and given daily (Monday-Friday) for increasing numbers of weeks, fibrosis was progressively reduced as the length of AVA treatment increased. However, AVA\u2019s effect on fibrosis decreased as the time between irradiation and post-irradiation AVA application increased.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These studies confirm the efficacy of AVA as a radioprotector and mitigator of both radiation-induced acute and late effects after high dose per fraction exposures while not protecting tumor cells to radiation exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1761003","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:21:53Z","timestamp":1771564913000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Avasopasem manganese acts as both a radioprotector and a radiomitigator of radiation-induced acute or late effects"],"prefix":"10.3389","volume":"16","author":[{"given":"Brock J.","family":"Sishc","sequence":"first","affiliation":[{"name":"Division of Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern Medical Center","place":["Dallas, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepti","family":"Ramnarain","sequence":"additional","affiliation":[{"name":"Division of Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern Medical Center","place":["Dallas, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zengfu","family":"Shang","sequence":"additional","affiliation":[{"name":"Division of Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern Medical Center","place":["Dallas, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Alves","sequence":"additional","affiliation":[{"name":"Division of Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern Medical Center","place":["Dallas, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Bloom","sequence":"additional","affiliation":[{"name":"Division of Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern Medical Center","place":["Dallas, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine, Colorado State University","place":["Ft Collins, CO, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debabrata","family":"Saha","sequence":"additional","affiliation":[{"name":"Division of Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern Medical Center","place":["Dallas, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis P.","family":"Riley","sequence":"additional","affiliation":[{"name":"Division of Molecular Radiation Biology, Department of Radiation Oncology, Galera Therapeutics","place":["Malvern, PA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L.","family":"Keene","sequence":"additional","affiliation":[{"name":"Division of Molecular Radiation Biology, Department of Radiation Oncology, Galera Therapeutics","place":["Malvern, PA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Beardsley","sequence":"additional","affiliation":[{"name":"Division of Molecular Radiation Biology, Department of Radiation Oncology, Galera Therapeutics","place":["Malvern, PA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Story","sequence":"additional","affiliation":[{"name":"Division of Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern Medical Center","place":["Dallas, TX, United States"]},{"name":"Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center","place":["Dallas, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.15537\/smj.2021.42.3.20210660","article-title":"Radiation therapy in head and neck cancer","volume":"42","author":"Alfouzan","year":"2021","journal-title":"Saudi Med J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.6233","article-title":"Radiotherapy side effects: integrating a survivorship clinical lens to better serve patients","volume":"27","author":"Dilalla","year":"2020","journal-title":"Curr Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21689","article-title":"Radiation therapy-associated toxicity: Etiology, management, and prevention","volume":"71","author":"Wang","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-022-00959-z","article-title":"Pathogenesis and amelioration of radiation-induced oral mucositis","volume":"23","author":"Lee","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12890-020-01376-4","article-title":"Radiation-induced lung injury: current evidence","volume":"21","author":"Arroyo-Hern\u00e1ndez","year":"2021","journal-title":"BMC Pulm Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.01.052","article-title":"Acute and late pulmonary effects after radiation therapy in childhood cancer survivors: A PENTEC comprehensive review","volume":"119","author":"Briere","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000502979","article-title":"Use of amifostine for cytoprotection during radiation therapy: A review","volume":"98","author":"King","year":"2020","journal-title":"Oncology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.12.027","article-title":"Decreasing the toxicity of radiation therapy: radioprotectors and radiomitigators being developed by the national cancer institute through small business innovation research contracts","volume":"104","author":"Zakeri","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B9","first-page":"4","article-title":"The need for biological countermeasures to mitigate the risk of space radiation-induced carcinogenesis, cardiovascular disease, and central nervous system deficiencies","volume":"35","author":"Sishc","year":"2022","journal-title":"Life Sci Space Res (Amst)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb3768","article-title":"Avasopasem manganese synergizes with hypofractionated radiation to ablate tumors through the generation of hydrogen peroxide","volume":"13","author":"Sishc","year":"2021","journal-title":"Sci Transl Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S267400","article-title":"Superoxide dismutase as an intervention for radiation therapy-associated toxicities: review and profile of avasopasem manganese as a treatment option for radiation-induced mucositis","volume":"15","author":"Sonis","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2230117","article-title":"Avasopasem for the treatment of radiotherapy-induced severe oral mucositis","volume":"32","author":"Sonis","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.06.063","article-title":"Two-year tumor outcomes of a phase 2B, randomized, double-blind trial of avasopasem manganese (GC4419) versus placebo to reduce severe oral mucositis owing to concurrent radiation therapy and cisplatin for head and neck cancer","volume":"114","author":"Anderson","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01507","article-title":"Phase IIb, randomized, double-blind trial of GC4419 versus placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer","volume":"37","author":"Anderson","year":"2019","journal-title":"J Clin Oncol"},{"key":"B15","article-title":"ROMAN: Phase 3 trial of avasopasem manganese (GC4419) for severe oral mucositis (SOM) in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer (LAHNC)","volume":"40","author":"Anderson","year":"2022","journal-title":"J Clin Oncol (JCO)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"101674","DOI":"10.1016\/j.adro.2024.101674","article-title":"Benefit of avasopasem manganese on severe oral mucositis in head and neck cancer in the ROMAN trial: unplanned secondary analysis","volume":"10","author":"Anderson","year":"2025","journal-title":"Adv Radiat Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1016\/j.ijrobp.2022.07.659","article-title":"Phase 2 open-label trial of avasopasem manganese (GC4419) for reduction of esophagitis in patients receiving chemoradiotherapy for nonmetastatic lung cancer","volume":"114","author":"Ciuba AC","year":"2022","journal-title":"Int J Radiat Oncol Biol Physics"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00478-3","article-title":"Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b\/2 trial","volume":"24","author":"Taniguchi","year":"2023","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"103527","DOI":"10.1016\/j.critrevonc.2021.103527","article-title":"Radiation recall reactions: An oncologic enigma","volume":"168","author":"McKay","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/1471-2164-14-372","article-title":"Distinct transcriptome profiles identified in normal human bronchial epithelial cells after exposure to \u03b3-rays and different elemental particles of high Z and energy","volume":"14","author":"Ding","year":"2013","journal-title":"BMC Genomics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3703","article-title":"Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins","volume":"64","author":"Ramirez","year":"2004","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e22023","DOI":"10.1371\/journal.pone.0022023","article-title":"Multipotent capacity of immortalized human bronchial epithelial cells","volume":"6","author":"Delgado","year":"2011","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1667\/RR13817.1","article-title":"Radiation quality and mutagenesis in human lymphoblastoid cells","volume":"182","author":"Liber","year":"2014","journal-title":"Radiat Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrt234","article-title":"Development of a small animal model to simulate clinical stereotactic body radiotherapy-induced central and peripheral lung injuries","volume":"55","author":"Hong","year":"2014","journal-title":"J Radiat Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"101139","DOI":"10.1016\/j.gendis.2023.101139","article-title":"PDLIM1 sustains DNA damage response by promoting chromatin relaxation and activating DNA-PK complex","volume":"11","author":"Lang","year":"2024","journal-title":"Genes Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0165-1161(89)90018-6","article-title":"A comparison of mutation induction at the tk and hprt loci in human lymphoblastoid cells; quantitative differences are due to an additional class of mutations at the autosomal tk locus","volume":"216","author":"Liber","year":"1989","journal-title":"Mutat Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00257","article-title":"Telomeres and telomerase in the radiation response: implications for instability, reprograming, and carcinogenesis","volume":"5","author":"Sishc","year":"2015","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e2711","DOI":"10.1038\/cddis.2017.136","article-title":"Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines","volume":"8","author":"Karanam","year":"2017","journal-title":"Cell Death Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"20210006","DOI":"10.1259\/bjro.20210006","article-title":"Comparison of quantitative and qualitative scoring approaches for radiation-induced pulmonary fibrosis as applied to a preliminary investigation into the efficacy of mesenchymal stem cell delivery methods in a rat model","volume":"2","author":"Wang","year":"2021","journal-title":"BJR Open"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-2184.35.s1.6.x","article-title":"Radiation-induced oral mucositis in mice: strain differences","author":"D\u00f6rr","year":"2002","journal-title":"Cell Prolif"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00154","article-title":"Single-dose radiation-induced oral mucositis mouse model","volume":"6","author":"Maria","year":"2016","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0819","article-title":"Prevention of radiation-induced oral mucositis after adenoviral vector-mediated transfer of the keratinocyte growth factor cDNA to mouse submandibular glands","volume":"15","author":"Zheng","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103539","article-title":"Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN)","volume":"89","author":"Anderson","year":"2025","journal-title":"eClinicalMedicine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2024.07.002","article-title":"Management of acute radiation syndrome","volume":"31","author":"Arnautou","year":"2024","journal-title":"Transfus Clin Biol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1761003\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:21:55Z","timestamp":1771564915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1761003\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":34,"alternative-id":["10.3389\/fonc.2026.1761003"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1761003","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"article-number":"1761003"}}